4.7 Article

Clinically feasible MTR is sensitive to cortical demyelination in MS

Journal

NEUROLOGY
Volume 80, Issue 3, Pages 246-252

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e31827deb99

Keywords

-

Funding

  1. NIH NINDS [P50 NS38667]
  2. CIHR (MOP) [84367]
  3. Multiple Sclerosis Scientific Research Foundation
  4. NIH
  5. National Multiple Sclerosis Society
  6. Biogen Idec
  7. Genzyme
  8. Bayer Healthcare
  9. EMD Serono
  10. Genentech
  11. Sanofi Aventis
  12. Serono Symposia International
  13. Teva
  14. NeuroRx Research
  15. Canadian Institutes for Health Research
  16. MS Society of Canada
  17. MS Society of Canada Foundation
  18. State of Ohio
  19. Pfizer

Ask authors/readers for more resources

Objective: Presently there is no clinically feasible imaging modality that can effectively detect cortical demyelination in patients with multiple sclerosis (MS). The objective of this study is to determine if clinically feasible magnetization transfer ratio (MTR) imaging is sensitive to cortical demyelination in MS. Methods: MRI were acquired in situ on 7 recently deceased patients with MS using clinically feasible sequences at 3 T, including relatively high-resolution T1-weighted and proton density-weighted images with/without a magnetization transfer pulse for calculation of MTR. The brains were rapidly removed and placed in fixative. Multiple cortical regions from each brain were immunostained for myelin proteolipid protein and classified as mostly myelinated (MMctx), mostly demyelinated (MDctx), or intermediately demyelinated (IDctx). MRIs were registered with the cortical sections so that the cortex corresponding to each cortical section could be identified, along with adjacent subcortical white matter (WM). Mean cortical MTR normalized to mean WM MTR was calculated for each cortical region. Linear mixed-effects models were used to test if mean normalized cortical MTR was significantly lower in demyelinated cortex. Results: We found that mean normalized cortical MTR was significantly lower in cortical tissue with any demyelination (IDctx or MDctx) compared to MMctx (demyelinated cortex: least-squares mean [LSM] = 0.797, SE = 0.007; MMctx: LSM = 0.837, SE = 0.006; p = 0.01, n = 89). Conclusions: This result demonstrates that clinically feasible MTR imaging is sensitive to cortical demyelination and suggests that MTR will be a useful tool to help detect MS cortical lesions in living patients with MS. Neurology (R) 2013;80:246-252

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available